DC4U Technologies
GlycoDC™ Platform modulating the immune system
The Netherlands
2 employees
Grant
Total: $6.90M
Biotechnology, Life Sciences +1
General Information
The Netherlands
BounceWatch is an independent company data service, not affiliated with DC4U Technologies. To contact DC4U Technologies, visit dc4u-technologies.nl.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does DC4U Technologies compare?
A PDF of DC4U Technologies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting DC4U Technologies soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
The Netherlands Market
Biotechnology
About DC4U Technologies
Business keywords: Life Science, Immunological Application, Glycobiology, Platform Technology, Immune System Modulation, Antigen Therapeutics
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | €1.70M | 1 |
|
25 Oct 2022 |
| Grant | €2.70M | 1 |
Eurostars
|
01 Nov 2016 |
| Grant | €2.50M | 1 |
Eurostars
|
01 Jan 2015 |
DC4U Technologies Alternatives & Competitors
View All Alternatives
Modulating immunity with the small—yet, mighty—nanobody
Memgen's Vision: Develop Life-Saving Cancer Immunotherapies
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer
FAQ About DC4U Technologies
Source: BounceWatch company record for DC4U Technologies, https://bouncewatch.com/company/dc4u-technologies, updated 1 December 2024. When citing, please name BounceWatch and link this page.
